SSRI treatment decreases prolactin and hyperthermic responses to mCPP

Psychopharmacology (Berl). 1997 Oct;133(3):305-8. doi: 10.1007/s002130050406.


We studied the effect of 3 weeks treatment with the selective serotonin re-uptake inhibitor (SSRI), paroxetine (30 mg daily), on the neuroendocrine and hyperthermic responses to the 5-HT2C receptor agonist, m-chlorophenylpiperazine (mCPP) (0.05 mg/kg i.v.), in seven healthy volunteers. Following paroxetine treatment, both the prolactin and hyperthermic responses to mCPP were significantly attenuated. These data are consistent with experimental animal studies indicating that repeated SSRI treatment leads to a functional desensitisation of 5-HT2C receptors. This effect may be linked to the anxiolytic properties of SSRIs.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Area Under Curve
  • Body Temperature / drug effects
  • Cross-Over Studies
  • Female
  • Fever / chemically induced*
  • Humans
  • Male
  • Middle Aged
  • Paroxetine / pharmacology*
  • Piperazines / pharmacology*
  • Prolactin / blood*
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Serotonin Receptor Agonists / pharmacology*
  • Single-Blind Method


  • Piperazines
  • Serotonin Receptor Agonists
  • Serotonin Uptake Inhibitors
  • Paroxetine
  • Prolactin
  • 1-(3-chlorophenyl)piperazine